Company Overview
Surrozen, Inc., a biotechnology company, discovers and develops product candidates to selectively modulate the Wnt pathway for tissue repair. Its lead product candidates are antibody-based therapeutics that target various disease areas, including diseases of the eye, intestine, liver, lung, retina, kidney, cochlea, cornea, skin, pancreas, and central nervous system. The company develops SZN-814, which combines Frizzled 4 (Fzd4 agonism) and vascular endothelial growth factor (VEGF antagonism) to treat diabetic macular edema (DME), neovascular age-related macular degeneration (wet AMD), and retinopathy indications; SZN-8143, which combines Fzd4 agonism, VEGF antagonism, and interleukin-6, or IL-6 for the treatment of DME/wet AMD/uveitic macular edema; and SZN-413, a Fzd4 targeted bi-specific antibody for the treatment of retinal vascular associated diseases. Surrozen, Inc. has a collaboration and license agreement with Boehringer Ingelheim International GmbH to research, develop, and commercialize Fzd4 bi-specific antibodies; and a research collaboration agreement with TCGFB, Inc. to discover antibody therapeutics targeting transforming growth factor beta, or TGF-ß, for the treatment of patients with idiopathic pulmonary fibrosis. Surrozen, Inc. was founded in 2015 and is headquartered in South San Francisco, California.
Why Investors Should Care
Generates a return on equity of 128.9%, reflecting efficient use of shareholder capital.
Recent Developments
- Dec 2025 Revenue of $3.48M (-67.4% YoY); net profit $-242.03M.
- Trailing 12 Months Year-on-year growth — revenue +408.6%, earnings -37.0%.
Growth & Price Performance
Compounded Sales Growth
| 5 Years: | - |
| 1 Year: | 408.60% |
Compounded Profit Growth
| 5 Years: | - |
| 1 Year: | -37.00% |
Stock Price Performance
| 1 Year: | +105.57% |
| 6 Months: | -24.53% |
| 3 Months: | -0.05% |
| 1 Month: | -19.28% |
Highlights auto-generated from reported financials and price data; not investment advice. Verify with official filings before acting.
- Price vs 50-DMABelow
- Price vs 200-DMABelow
- RSI (14)36.09 · Neutral
Auto-generated from price history and fundamentals; not investment advice.
Price Chart
Technical Trend
Computed from daily close history using EMA cross, slope, and RSI signals.
Note: intraday data is not stored locally. “Hourly” uses the most recent 10 daily candles as a short-term proxy.
Fundamental Growth Charts
No fundamental data available for this stock.
Interactive charts for Revenue, Net Income, EBITDA, Free Cash Flow, EPS, ROE, ROCE, Gross/Net/Operating Margin and more — switch metric and period using the dropdowns above. CAGR is computed across the displayed window (quarterly CAGR is annualised). Visual growth charts make it easy to spot multi-year compounding trends at a glance — far faster than reading raw numbers in a table.
PROS
- Strong return on equity of 128.9%.
CONS
- Trading 39.4% below its 52-week high.
- In a downtrend (50-DMA below 200-DMA).
* The pros and cons are auto-generated from financial metrics.
Valuation
Growth (CAGR)
Profitability & Returns
Balance Sheet & Liquidity
Ownership
Financial Snapshot
Peer comparison
Peer companies in the same sector (Healthcare).
| # | Name | CMP $ | P/E | Mkt Cap | Div Yld % | ROCE % | ROE % | Rev CAGR 5Y % | Profit CAGR 5Y % |
|---|---|---|---|---|---|---|---|---|---|
| 1 | SRZN Surrozen, Inc. PHARMA | 20.68 | -0.52 | $243.06M | 0.00% | -47.40% | 128.90% | - | - |
| 2 | LLY Eli Lilly and Company SPXR3KPHARMA | 1,123.91 | 37.80 | $1.00T | 0.60% | - | 102.29% | 7.20% | 11.41% |
| 3 | JNJ Johnson & Johnson SPXR3KPHARMA | 269.12 | 31.22 | $648.55B | 1.98% | 14.88% | 25.74% | 2.43% | 4.76% |
| 4 | ABBV AbbVie Inc. SPXR3KPHARMA | 248.78 | 70.48 | $439.62B | 2.78% | 10.47% | -129.24% | 1.75% | -29.06% |
| 5 | MRK Merck & Co., Inc. SPXR3KPHARMA | 148.46 | 118.77 | $366.28B | 2.31% | - | 6.96% | 5.64% | 10.01% |
| 6 | UNH UnitedHealth Group Incorporated SPXR3KPHARMA | 400.84 | 25.74 | $359.79B | 2.47% | 9.74% | 14.15% | 10.40% | 5.43% |
| 7 | NVS Novartis AG PHARMA | 137.70 | 20.80 | $261.73B | 3.36% | 21.09% | 30.35% | 9.25% | 26.22% |
| 8 | AZN AstraZeneca PLC NDXPHARMA | 160.04 | 23.99 | $248.20B | 2.00% | 15.97% | 21.96% | 9.82% | 45.96% |
| 9 | TMO Thermo Fisher Scientific Inc. SPXR3KPHARMA | 603.02 | 32.49 | $222.97B | 0.29% | 8.14% | 13.51% | 8.81% | 12.95% |
Financial Statements Quarterly Results · Profit & Loss · Balance Sheet · Cash Flows · Ratios
Quarterly Results
Figures in USD.
| Metric | Sep 2020 | Mar 2021 | Jun 2021 | Sep 2021 | Mar 2022 | Jun 2022 | Sep 2022 | Mar 2023 | Jun 2023 | Sep 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | - | - | - | - | - | - | - | - | - | - | - | - | 10.00M | - | 983.00K | 983.00K | 983.00K | 528.00K | 5.00M |
| Cost of Revenue | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Operating Expenses | - | - | - | - | - | - | - | - | - | - | - | - | - | - | 10.53M | 10.00M | 11.87M | 13.17M | 15.46M |
| Operating Income | -8.64M | -13.03M | -12.66M | -13.71M | -14.49M | -14.07M | -13.61M | -14.59M | -10.28M | -11.19M | -9.13M | -9.05M | 1.23M | - | -9.55M | -9.02M | -10.88M | -12.64M | -10.46M |
| EBITDA | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -9.26M | -8.88M | -10.82M | -12.59M | -10.39M |
| Interest Expense | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Pretax Income | - | - | - | - | - | - | - | - | - | - | - | - | - | - | -26.97M | 39.75M | -71.64M | -183.16M | -127.50M |
| Tax Provision | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - | - |
| Net Income | -8.63M | -13.02M | -12.65M | -14.02M | -7.95M | -13.93M | -13.36M | -14.30M | -9.39M | -10.45M | -8.83M | -25.26M | -1.43M | - | -26.97M | 39.75M | -71.64M | -183.16M | -127.50M |
| Diluted EPS | - | - | -0.69 | -0.51 | -0.23 | -0.40 | -0.38 | -7.16 | -4.68 | -5.14 | -4.24 | -7.99 | -0.44 | - | -7.43 | 2.55 | -8.36 | - | -11.65 |
| R&D Expense | 6.96M | 8.60M | 10.27M | 10.42M | 9.37M | 9.58M | 8.62M | 8.09M | 6.94M | 6.11M | 5.25M | 5.33M | 5.20M | - | 6.56M | 6.04M | 7.77M | - | 9.33M |
Profit & Loss (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Revenue | - | 0 | 12.50M | 0 | 10.65M | 3.48M |
| Cost of Revenue | - | - | - | - | - | - |
| Gross Profit | - | - | - | - | - | - |
| Operating Expenses | - | - | 56.84M | 43.03M | 36.19M | 45.57M |
| Operating Income | -32.81M | -54.39M | -44.34M | -43.03M | -25.54M | -42.09M |
| EBITDA | - | - | -42.38M | -41.12M | -24.10M | -41.55M |
| Interest Expense | - | - | - | - | - | - |
| Pretax Income | - | - | -36.00M | -43.04M | -63.56M | -242.03M |
| Tax Provision | - | - | - | - | - | - |
| Net Income | -32.72M | -54.65M | -36.00M | -43.04M | -63.56M | -242.03M |
| Diluted EPS | - | -2.21 | -15.60 | -21.33 | -21.67 | -32.37 |
| R&D Expense | 25.68M | 40.18M | 37.01M | 27.23M | 21.13M | 29.36M |
Balance Sheet (Annual)
Figures in USD.
| Metric | Dec 2019 | Aug 2020 | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|---|---|
| Total Assets | - | - | 62.06M | - | 89.44M | 46.08M | 48.47M | 98.73M |
| Current Assets | - | - | - | - | 81.31M | 41.13M | 38.93M | 91.56M |
| Cash & Equivalents | - | - | 34.98M | - | 24.69M | 36.04M | 34.56M | 89.25M |
| Inventory | - | - | - | - | - | - | - | - |
| Receivables | - | - | - | - | 1.98M | 2.15M | 2.04M | 0 |
| Total Liabilities | - | - | 14.77M | - | 13.43M | 8.14M | 69.85M | 286.49M |
| Current Liabilities | - | - | 7.28M | - | 9.73M | 7.15M | 7.32M | 9.93M |
| Long Term Debt | - | - | - | - | - | - | - | - |
| Total Debt | - | - | - | - | 5.60M | 3.38M | 8.47M | 6.64M |
| Total Equity | 29.39M | 0 | 47.29M | - | 76.00M | 37.94M | -21.38M | -187.76M |
| Shares Outstanding | - | - | - | - | 2.01M | 2.06M | 3.26M | 9.77M |
Cash Flows (Annual)
Figures in USD.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Operating Cash Flow | -29.10M | - | -44.15M | -40.36M | -17.63M | -30.24M |
| Investing Cash Flow | -15.07M | - | 38.31M | 51.72M | -26.00K | -128.00K |
| Financing Cash Flow | 50.05M | - | -2.56M | 276.00K | 16.18M | 85.05M |
| Capital Expenditure | -874.00K | - | -728.00K | -398.00K | -26.00K | -128.00K |
| Free Cash Flow | -29.97M | - | -44.87M | -40.76M | -17.65M | -30.37M |
| Net Change in Cash | - | - | -8.40M | 11.64M | -1.48M | 54.68M |
| Share Buybacks | - | 0 | 2.61M | 0 | - | - |
Ratios (Annual)
Figures in %.
| Metric | Dec 2020 | Dec 2021 | Dec 2022 | Dec 2023 | Dec 2024 | Dec 2025 |
|---|---|---|---|---|---|---|
| Gross Margin % | - | - | - | - | - | - |
| Operating Margin % | - | - | -354.7% | - | -239.7% | -1,210.6% |
| Net Margin % | - | - | -288.0% | - | -596.6% | -6,960.8% |
| ROE % | -69.2% | - | -47.4% | -113.5% | 297.3% | 128.9% |
| ROCE % | -59.9% | - | -55.6% | -110.5% | -62.1% | -47.4% |
Shareholding Pattern
Top Institutional Holders
| # | Holder | % Held | Shares | Value |
|---|---|---|---|---|
| 1 | Column Group LLC | 16.51% | 1.92M | $31.73M |
| 2 | TCG Crossover Management, LLC | 12.69% | 1.47M | $24.38M |
| 3 | Boxer Capital Management, LLC | 9.52% | 1.11M | $18.30M |
| 4 | Millennium Management Llc | 5.88% | 683.08K | $11.30M |
| 5 | Point72 Asset Management, L.P. | 5.72% | 664.27K | $10.99M |
| 6 | Venrock Adviser, LLC | 5.45% | 632.93K | $10.48M |
| 7 | Stempoint Capital LP | 5.19% | 602.80K | $9.98M |
| 8 | Perceptive Advisors Llc | 4.34% | 503.99K | $8.34M |
| 9 | Spruce Street Capital LP | 3.72% | 432.04K | $7.15M |
| 10 | Blackrock Inc. | 3.40% | 394.86K | $6.53M |
Analyst View
Analyst aggregate. Targets and ratings update periodically; not investment advice.
Latest News
Recent headlines for SRZN
Surrozen Announces Submission of IND Application for SZN-8141 for the Treatment of Diabetic Macular Edema - Stock Titan
<a href="https://news.google.com/rss/articles/CBMivAFBVV95cUxNZ21ZWnlmQ2l2dEN3bHZnVW5TLWRUT2lmZGJMQ3c4VXREaXUyR0Z3X3RQYkRvSWd1eE04QTlSLUpNMnZnOGlzMEJleFdGTm1VbS1aWE9udTQtLWdsZmhOT0RaZi1Iei1jWEZ4WDJydFQwSnpWV2RHUmtjaVNQNFItcEJVOUp5Q2dNbjlGSj…
Discipline and Rules-Based Execution in SRZN Response - Stock Traders Daily
<a href="https://news.google.com/rss/articles/CBMizgFBVV95cUxNNTJiUnZOdC1lVzFQZW9oVEVQQTZ6U3BkLXRXbElQbVhEX2Rqb1gxUnpoVGNXbVdoVU5sUFZaNXJ4T3dtTmpNOEliVVI4LWpRVGlhME83NmNfUkxBX2tfdE1hdzFsTDJQdTlqMlRfM19hTGY5TmxXaWVEMzhVbGpIVEpfbkFLUGJXWUdJNF…
We're Not Very Worried About Surrozen's (NASDAQ:SRZN) Cash Burn Rate - finance.yahoo.com
<a href="https://news.google.com/rss/articles/CBMinAFBVV95cUxPZVQ5SnQ0azRUUldwa3gtbW84dEZJRWRrODBmT3FmZGcxbEkwanVZdE05aUJQbVpTTXZySnFJdk02NVpsZUJITUhyWDBRS2I3SDhhMU95d1R6c3BWZHpNTEZIWW0zak14Ujg5R090R3Q5UHFvRUtwZk1EN3NHNFVuZnFlU3B5ei1jS05LZD…
Two healthcare talks are planned for September. Surrozen management will speak. - Stock Titan
<a href="https://news.google.com/rss/articles/CBMiqgFBVV95cUxOTVpoOVVqSTdvcENoYVI0am5VaTVEb1hJRUF1ZUR0b1B3a01LOVI4UXBQWURFOE5PQlhNVGdFYkVCV3NURzBDaHM1dkRkY1JONDZQQ3A0UEFMRm00SHNLdEVpbEJLRE1BdnFYNlFuTjVxQ2ViZHZES3JHRkJlbjZXVHJfUTRRcHFmTmNIaF…
SRZN - Finviz
<a href="https://news.google.com/rss/articles/CBMiRkFVX3lxTE43WVEyTHI0TGRVaVBHYUVtQl9YWDN4UGtXNVpOQzhBLUl0cFoyQ2dXYXFReFN6SUlNVmt1UGxWZDRqSGdDaWc?oc=5" target="_blank">SRZN</a> <font color="#6f6f6f">Finviz</font>…
Insider Stock Purchases: March 26, 2026 - Quiver Quantitative
<a href="https://news.google.com/rss/articles/CBMiggFBVV95cUxPS1VfaHZHMERPUVRPNG82bmV0UEFmcUZXcG91VkhmVTdwUm9vRGZLLURmVVVxZ2lKSnplRzFWc2FhcE1OanVwSk1KMjNfOFZaZmFvbEt6X1JVMkJQTS1HVFcyRk1WUFkzRTBMS0h6TDdaNlYtMzR1RW1iSjVuWXg5aktR?oc=5" target=…
SRZN — Frequently Asked Questions
What is the current share price of Surrozen, Inc. (SRZN)?
As of 2026-09-19 21:16 PDT, Surrozen, Inc. (SRZN) trades at $20.68 on NasdaqCM. Its 52-week range is $10.06 to $34.13.
What is the market capitalisation of SRZN?
Surrozen, Inc. (SRZN) has a market capitalisation of $243.06M on NasdaqCM.
What is the P/E ratio of SRZN?
SRZN trades at a trailing price-to-earnings (P/E) ratio of -0.52. The industry average P/E is 24.83. Its price-to-book (P/B) ratio is -0.89.
What is the return on equity (ROE) of SRZN?
SRZN has a return on equity (ROE) of 128.90%. Its return on capital employed (ROCE) is -47.40%.
Is SRZN a good stock to buy?
This page provides a data-driven analysis of Surrozen, Inc. (SRZN), including valuation ratios, profitability, growth trends, auto-generated pros and cons, peer comparison and AI exposure. Review these fundamentals alongside your own research and risk tolerance. This is informational content, not investment advice.